DK0938316T3 - Opioidantagonistholdig galenisk formulering - Google Patents
Opioidantagonistholdig galenisk formuleringInfo
- Publication number
- DK0938316T3 DK0938316T3 DK97954355T DK97954355T DK0938316T3 DK 0938316 T3 DK0938316 T3 DK 0938316T3 DK 97954355 T DK97954355 T DK 97954355T DK 97954355 T DK97954355 T DK 97954355T DK 0938316 T3 DK0938316 T3 DK 0938316T3
- Authority
- DK
- Denmark
- Prior art keywords
- opioid antagonist
- galenic formulation
- active substance
- containing galenic
- analgesic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19651551A DE19651551C2 (de) | 1996-12-11 | 1996-12-11 | Opioidantagonisthaltige galenische Formulierung |
PCT/EP1997/006789 WO1998025613A2 (de) | 1996-12-11 | 1997-12-04 | Opioidantagonisthaltige galenische formulierung |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0938316T3 true DK0938316T3 (da) | 2002-10-21 |
Family
ID=7814396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97954355T DK0938316T3 (da) | 1996-12-11 | 1997-12-04 | Opioidantagonistholdig galenisk formulering |
Country Status (10)
Country | Link |
---|---|
US (1) | US6419959B1 (da) |
EP (1) | EP0938316B1 (da) |
JP (1) | JP5065548B2 (da) |
AT (1) | ATE220907T1 (da) |
CA (1) | CA2273353C (da) |
DE (2) | DE19651551C2 (da) |
DK (1) | DK0938316T3 (da) |
ES (1) | ES2181055T3 (da) |
PT (1) | PT938316E (da) |
WO (1) | WO1998025613A2 (da) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
ME00527B (me) | 1997-12-22 | 2011-10-10 | Euro Celtique Sa | Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista |
BR9813826A (pt) | 1997-12-22 | 2000-10-10 | Euro Celtique Sa | Potencial de uso abusivo de administração oral de opióide analgésico |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
PT2277521E (pt) * | 2000-02-08 | 2015-07-01 | Euro Celtique Sa | Formulações orais de agonistas de opióides resistentes a adulteração |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
CN101439024A (zh) * | 2001-05-11 | 2009-05-27 | 恩德制药公司 | 抗滥用阿片样物质剂型 |
AU2002314967B2 (en) | 2001-06-05 | 2007-09-20 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
PT1416842E (pt) | 2001-07-18 | 2009-03-31 | Euro Celtique Sa | Composições farmacêuticas de oxicodona e naloxona |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
SI1414451T1 (sl) | 2001-08-06 | 2009-10-31 | Euro Celtique Sa | Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom |
US7056500B2 (en) | 2001-10-18 | 2006-06-06 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
LT2425824T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
EP2422772A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
MXPA05010819A (es) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. |
AU2013203378B2 (en) * | 2003-04-08 | 2016-09-15 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
PT1615646E (pt) * | 2003-04-08 | 2015-02-12 | Progenics Pharm Inc | Formulações farmacêuticas com metilnaltrexona |
CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
US20060182692A1 (en) * | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
EA018427B1 (ru) * | 2003-12-16 | 2013-07-30 | Нектар Терапьютикс | Химически модифицированный налоксон |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
BRPI0606587A2 (pt) * | 2005-01-20 | 2009-07-07 | Progenics Pharmaceuticais Inc | uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória |
EP2289491A1 (en) * | 2005-01-28 | 2011-03-02 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
KR101486228B1 (ko) | 2006-06-19 | 2015-01-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
CA2682129A1 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
TWI553009B (zh) | 2007-03-29 | 2016-10-11 | 普吉尼製藥公司 | 末梢性類鴉片受體拮抗劑及其用途 |
JP5469593B2 (ja) | 2007-03-29 | 2014-04-16 | ワイス・エルエルシー | 末梢性オピオイド受容体アンタゴニストおよびその使用 |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
US8883817B2 (en) * | 2007-10-18 | 2014-11-11 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
WO2009099411A1 (en) | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
ES2620373T3 (es) * | 2008-07-01 | 2017-06-28 | University Of Chicago | Partículas que contienen un antagonista del receptor de opioides periférico |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
DK2405915T3 (da) | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | Farmaceutiske sammensætninger med øjeblikkelig frigivelse omfattende oxycodon og naloxon |
WO2010151741A1 (en) | 2009-06-25 | 2010-12-29 | Elite Laboratories, Inc. | Abuse resistant oral dosage forms |
NZ703564A (en) | 2010-03-11 | 2016-08-26 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
SG184523A1 (en) | 2010-05-10 | 2012-11-29 | Euro Celtique Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
ES2642788T3 (es) | 2010-05-10 | 2017-11-20 | Euro-Celtique S.A. | Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos |
AU2011252041B2 (en) | 2010-05-10 | 2014-04-03 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
EP3024461B1 (en) | 2013-07-23 | 2020-05-13 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
KR20160060768A (ko) | 2013-11-13 | 2016-05-30 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
US10105360B2 (en) | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
US9456986B2 (en) | 2013-12-11 | 2016-10-04 | Develco Pharma Schweiz Ag | Naloxone mono preparation and multilayer tablet |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
JP6686013B2 (ja) | 2014-10-17 | 2020-04-22 | サリックス ファーマスーティカルズ,インコーポレーテッド | 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用 |
WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US20160256451A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
US20160256452A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time |
WO2016193456A2 (en) | 2015-06-03 | 2016-12-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation |
EP3290027A1 (en) | 2016-09-02 | 2018-03-07 | Develco Pharma Schweiz AG | Method and composition for the treatment of opioid induced constipation |
CA3137488C (en) | 2019-05-07 | 2023-10-31 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
EP0103636B1 (en) * | 1982-03-16 | 1990-09-12 | Rockefeller University | Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4774230A (en) * | 1988-03-26 | 1988-09-27 | Ivax Laboratories, Inc. | Glucuronic acid derivatives of opioid antagonists |
EP0352361A1 (en) * | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
ATE211906T1 (de) * | 1996-03-12 | 2002-02-15 | Alza Corp | Zusammensetzung und dosisform mit einem opioid- antagonisten |
-
1996
- 1996-12-11 DE DE19651551A patent/DE19651551C2/de not_active Expired - Fee Related
-
1997
- 1997-12-04 PT PT97954355T patent/PT938316E/pt unknown
- 1997-12-04 US US09/319,818 patent/US6419959B1/en not_active Expired - Fee Related
- 1997-12-04 EP EP97954355A patent/EP0938316B1/de not_active Expired - Lifetime
- 1997-12-04 AT AT97954355T patent/ATE220907T1/de active
- 1997-12-04 CA CA2273353A patent/CA2273353C/en not_active Expired - Fee Related
- 1997-12-04 ES ES97954355T patent/ES2181055T3/es not_active Expired - Lifetime
- 1997-12-04 DE DE59707812T patent/DE59707812D1/de not_active Expired - Lifetime
- 1997-12-04 DK DK97954355T patent/DK0938316T3/da active
- 1997-12-04 WO PCT/EP1997/006789 patent/WO1998025613A2/de active IP Right Grant
- 1997-12-04 JP JP52618398A patent/JP5065548B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1998025613A3 (de) | 1998-10-29 |
EP0938316A2 (de) | 1999-09-01 |
DE19651551A1 (de) | 1998-06-18 |
JP5065548B2 (ja) | 2012-11-07 |
ATE220907T1 (de) | 2002-08-15 |
US6419959B1 (en) | 2002-07-16 |
DE59707812D1 (de) | 2002-08-29 |
JP2001505897A (ja) | 2001-05-08 |
WO1998025613A2 (de) | 1998-06-18 |
CA2273353A1 (en) | 1998-06-18 |
EP0938316B1 (de) | 2002-07-24 |
ES2181055T3 (es) | 2003-02-16 |
DE19651551C2 (de) | 2000-02-03 |
PT938316E (pt) | 2002-12-31 |
CA2273353C (en) | 2011-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0938316T3 (da) | Opioidantagonistholdig galenisk formulering | |
IL136285A0 (en) | Pharmaceutical compositions containing an acid-labile active component | |
ATE202280T1 (de) | Filmbildende pharmazeutische zusammensetzungen zur transdermalen verabreichung | |
DK1183014T3 (da) | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse | |
EE200200357A (et) | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid | |
IL116673A (en) | Stable oral pharmaceutical composition containing an acid labile benzimidazole | |
DE69727922D1 (de) | Schnell zerfallende orale dosierungsform | |
TR200103613T2 (tr) | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. | |
NO20014035D0 (no) | System for oral administrasjon av medikament | |
WO2001082897A3 (en) | Liposome drug delivery | |
TR199900336T2 (xx) | EAA antagonistleri olarak tetrahidrokinolin t�revleri. | |
NO20004788L (no) | Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoidantagonist og en NMDA- reseptorkompleksmodulator | |
DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
ZA200308221B (en) | Pharmaceutical compositions for oral and topical administration. | |
DK1225902T3 (da) | Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden | |
NL193820B (nl) | Vaste farmaceutische doseringsvorm voor orale toediening van Ibuprofen. | |
PL348202A1 (en) | Pharmaceutically active composition and dispensing device | |
TR200200683T2 (tr) | Oral kontrollü salıverme formülasyonları. | |
FR2793685B1 (fr) | Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation | |
AR002191A1 (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion | |
AU5072000A (en) | Pharmaceutical composition for nasally administering water-soluble active substances | |
MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
AU2369801A (en) | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation | |
ATE234096T1 (de) | Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid | |
MY152490A (en) | New oral formulation |